Clinical trial
Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous…
NCT00043823 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00043823 |
|---|---|
| Title | Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer |
| Official title | Safety and Efficacy of Recombinant Humanized Monoclonal Anti-VEGF Antibody rhuMAb VEGF and EGFR Tyrosine Kinase Inhibitor OSI-774 for Locally Advanced or Metastatic Non-Squamous Cell NSCLC in Patients Who Have Been Previously Treated |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genentech, Inc. Industry Vanderbilt-Ingram Cancer Center |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Avastin, Tarceva |
| Enrollment | 41 |
| Start date | Aug 1, 2002 |
| Primary completion | May 15, 2006 |
| Completion | May 15, 2006 |
| First posted | Aug 15, 2002 |
| Last update posted | Nov 7, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: